WealthTrust Fairport’s Akebia Therapeutics AKBA Stock Holding History

WealthTrust Fairport’s Portfolio AKBA Stock Details AKBA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	$2K	Hold	256	–	–	﹤0.01%	400
2018 Q4	$1K	Buy	+256	New	+$2K	﹤0.01%	391
2018 Q2	–	Sell	-650	Closed	-$6K	–	500
2018 Q1	$6K	Buy	+650	New	+$9.09K	﹤0.01%	416

Other funds holding AKBA

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

WealthTrust Fairport's AKBA Position: Q1 2019 in Review

WealthTrust Fairport held its Akebia Therapeutics (AKBA) position steady in Q1 2019 at 256 shares worth $2K. The position accounts for ﹤0.01% of the portfolio, ranked #400.

WealthTrust Fairport first reported a position in AKBA in Q1 2018 and has held it in 3 quarters since. The position peaked at $6K in Q1 2018. 169 funds tracked by Wall St. Rank hold AKBA as of Q1 2019.

WealthTrust Fairport held 256 shares of Akebia Therapeutics worth $2K as of Q1 2019.
WealthTrust Fairport left its Akebia Therapeutics share count unchanged in Q1 2019.
Akebia Therapeutics made up ﹤0.01% of WealthTrust Fairport's portfolio in Q1 2019, its #400 holding.
WealthTrust Fairport first reported a position in Akebia Therapeutics in Q1 2018 and has held it in 3 quarters since.
WealthTrust Fairport's Akebia Therapeutics position peaked at $6K in Q1 2018.
169 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2019.

Based on WealthTrust Fairport's 13F filing for Q1 2019, filed 15 May 2019.